Capability
Protocol development
The protocol is where strategy becomes operational reality. We author and shepherd documents so medical, safety, stats, operations, and CMC each see their stake—and so reviewers can trace every objective and assessment back to the evidence plan you intend to defend.
Ambiguity in the protocol becomes expensive ambiguity in the trial: amendment churn, query storms, inspection findings, and CSR narratives that strain to reconcile what sites were told to do with what statistics planned to analyze. We focus on clarity at the source—especially for registrational, pediatric, and combination studies where every paragraph is contested.
The protocol challenge
Protocols sit at the intersection of science, regulation, and operations. Medical teams want maximum information; sites want feasible visits; statistics wants clean estimands; safety wants visibility; CMC and device groups want their obligations visible. When those tensions are not resolved in the document, they surface as amendments, protocol deviations, and analyses that reviewers question. For combination and novel-modality trials, the protocol is also the primary artifact partners and regulators use to judge whether the study can answer the causal questions it claims to answer.
Strong protocol development is therefore both writing and facilitation: surfacing hidden assumptions, forcing decisions on edge cases, and aligning language with the SAP and IB so the trial executes as a single system. That is the standard we apply—whether we draft full text or lead a cross-functional rewrite before finalization.
Where we focus
Authoring and structure
We build coherent section logic—objectives flowing to endpoints, endpoints to assessments, assessments to visit schedule— with explicit handling of intercurrent events, concomitant medications, and rescue rules. We align inclusion and exclusion language with feasibility and with the target population claims you intend to support, calling out where stringency trades off against generalizability.
Agency interactions
For Q-Sub, scientific advice, and pre-IND discussions, we help frame questions that elicit actionable feedback, assemble briefing packages that match the questions, and draft anticipated concerns with response strategies. After meetings, we translate agreements into protocol and SAP language so commitments are not lost in slide decks.
Cross-functional alignment
We run structured reviews with medical, safety, biostatistics, clinical operations, PV, and—where relevant—CMC and device owners. The output is a decision log embedded in tracked changes: what was debated, what was decided, and what remains a residual risk for governance escalation.
Operational realism
We push back on schedules that ignore patient burden or site capacity, and we surface DCT, imaging, and specialty lab burdens early. The goal is a protocol sites can execute with high fidelity, because execution quality is part of the evidence story.
What we deliver
- Full-protocol and amendment drafts with integrated synopses and operational annotations.
- Alignment memos linking protocol text to SAP, IB, and ICF where cross-document consistency matters.
- Q-Sub and meeting briefing packages with question lists, data exhibits, and fallback positions.
- Red-team reviews simulating agency or IRB scrutiny on high-risk sections.
- Facilitation of cross-functional comment resolution and version control discipline.
- Handoff notes for medical monitors and CRAs on ambiguous clinical judgment areas.
Outcomes you can expect
- Fewer preventable amendments driven by unresolved estimand or assessment definitions.
- Cleaner inspections and submissions because the protocol, SAP, and CSR tell one story.
- Faster turnaround on reviews when decisions are pre-made and documented.
- Lower site burden and deviation rates where schedules were stress-tested for feasibility.
How we work
We treat the protocol as the contract between science and operations. lotor lab invests in the uncomfortable conversations early—rescue rules, imaging progression, unscheduled visits—so they do not explode during database lock. Our bias is clarity and feasibility over theoretical elegance that sites cannot implement.
We complement your medical writers and study directors; we do not replace accountability for sign-off. Engagements may be end-to-end authorship, surgical support on contested sections, or meeting-only facilitation depending on team bandwidth and trial risk.
When teams bring us in
- Registrational, pediatric, oncology, or combination trials with high amendment cost and scrutiny.
- Recovery from clinical holds, major agency feedback, or failed inspections requiring protocol revision.
- Small biotech teams without a full medical writing function facing Big Pharma–scale complexity.
- Partnered trials where protocol language must satisfy multiple quality systems and review bodies.